

14 October 2026

ASX Limited
Market Announcements Office
Level 10
20 Bond Street
SYDNEY NSW 2000

Dear Sir/Madam

RESULTS OF 2026 ANNUAL GENERAL MEETING

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Yours sincerely,

PRESCIENT THERAPEUTICS LIMITED



Melanie Leydin
Company Secretary

Prescient Therapeutics Limited
2026 Annual General Meeting
Wednesday, 14 October 2026
Voting Results

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth)

Resolution Details				Show of Hands or Poll	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Res. Type	If s250U applies	S or P	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1	Adoption of Remuneration Report	Ordinary	N/A	P	53,054,171 87.23%	4,573,544 7.52%	3,196,198 5.25%	1,693,393	78,402,247 94.49%	4,573,544 5.51%	1,693,393	Carried
2	Re-election of Dr Ellen Feigal as a Director of the Company	Ordinary	N/A	P	74,857,807 93.89%	1,996,453 2.50%	2,878,642 3.61%	1,034,615	98,455,883 96.81%	3,246,453 3.19%	1,034,615	Carried
3	Re-election of Dr Gavin Shepherd as a Director of the Company	Ordinary	N/A	P	72,442,807 90.86%	4,396,453 5.51%	2,893,642 3.58%	1,034,615	97,290,883 95.68%	4,396,453 4.32%	1,034,615	Carried
4	Approval of 10% Placement Capacity	Special	N/A	P	72,918,427 90.33%	4,911,881 6.08%	2,893,642	43,567	74,168,427 72.23%	28,509,957 27.77%	43,567	Not Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.